Table 1 Patients’ characteristics
From: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
Patient number | 101 |
|---|---|
Median age (years) | 60 |
Histological subtype | |
 Serous | 79 (78, 3%) |
 Endometrioid | 7 (7%) |
 Mucinous | 2 (1, 9%) |
 Clear cell | 2 (1, 9%) |
 Mixed | 3 (2, 9%) |
 Other/not specifed | 8 (8%) |
Grading | |
 G1 | 0 |
 G2 | 7 (7%) |
 G3 | 94 (93%) |
Staging (FIGO) | |
 IC | 1 (0, 9%) |
 IIA | 4 (3, 9%) |
 IIB | 7 (7%) |
 IIIA | 4 (3, 9%) |
 IIIB | 8 (8%) |
 IIIC | 56 (55, 5%) |
 IV | 21 (20, 8%) |
PFI | |
 < 6 months | 65 (64, 4%) |
 ≥ 6 months | 36 (35, 6%) |
Number of previous chemoterapies | |
 1 | 82 (87, 3%) |
 2 | 10 (10, 6%) |
 ≥ 3 | 2 (2, 1%) |
PLD-based regimen | |
 PLD monotherapy | 54 (53, 4%) |
 Carbo-PLD | 30 (29, 7%) |
 Trabe-PLD | 17 (16, 9%) |
CA-125 mean value (UI/mL) | |
 Pre-PLD treatment | 1142 |
 Post-PLD treatment | 1493 |
BRCA status | |
 BRCA 1–2 mutation | 11 (10, 9%) |
 BRCA 1–2 wild-type | 12 (11, 9%) |
 VUS/HRD | 6 (5, 9%) |
 Unknown | 72 (71, 3%) |